TP-0903

AXL inhibitor · Sumitomo Pharma America, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TP-0903, covering 2021-02-02 to 2021-02-02. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL [Phase 1, Phase 2]

See pricing